Business Wire

Mirum’s LIVMARLI® Now Authorized in Canada for Cholestatic Pruritus in Patients with Alagille Syndrome

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that LIVMARLI® (maralixibat oral solution) has been authorized by Health Canada for the treatment of ...
Business Wire

Mirum Presents New Data from LIVMARLI Phase 3 PFIC Study and ALGS Infant Study in Late-Breaker Presentations at The Liver Meeting of AASLD

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), today presented new data from LIVMARLI® (maralixibat) oral solution studies, including two late-breaker presentations, ...
Business Insider

CANbridge Announces Marketing Approval of CAN108 (/LIVMARLI®) in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome (ALGS)

BEIJING and BURLINGTON, Mass., Oct. 8, 2023 /PRNewswire/ -- CANbridge Pharmaceuticals Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, ...